LUNDBECK'S CIPRALEX GETS EU APPROVAL FOR TREATMENT OF GAD

H Lundbeck AS said the European health authorities today approved its Cipralex drug for treating generalised anxiety disorder. The approval is based on seven clinical studies involving more than 1,600 patients. In Europe, Cipralex is already approved for the treatment of depression, social disorders and panic disorders, the three anxiety disorders that affect most patients, the company said.

Forbes (http://www.forbes.com/markets/feeds/afx/2005/09/22/afx2238336.html)